TherapeuticsMD (TXMD) Given “Buy” Rating at Noble Financial
Other analysts also recently issued research reports about the stock. Oppenheimer set a $10.00 price objective on shares of TherapeuticsMD and gave the stock a buy rating in a report on Wednesday. Deutsche Bank set a $9.00 price objective on shares of TherapeuticsMD and gave the stock a buy rating in a report on Wednesday. BidaskClub upgraded shares of TherapeuticsMD from a strong sell rating to a sell rating in a report on Tuesday, December 12th. Morgan Stanley assumed coverage on shares of TherapeuticsMD in a report on Friday, September 8th. They set an equal weight rating and a $6.00 price objective for the company. Finally, Cantor Fitzgerald restated a buy rating and set a $31.00 price objective on shares of TherapeuticsMD in a report on Wednesday, November 29th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $14.88.
TherapeuticsMD (TXMD) traded down $0.11 during midday trading on Wednesday, reaching $6.06. 6,273,200 shares of the company were exchanged, compared to its average volume of 2,932,273. TherapeuticsMD has a 1-year low of $3.50 and a 1-year high of $8.30.
In other TherapeuticsMD news, Director Tommy G. Thompson bought 5,000 shares of TherapeuticsMD stock in a transaction dated Friday, December 8th. The stock was purchased at an average price of $6.21 per share, for a total transaction of $31,050.00. Following the completion of the purchase, the director now directly owns 3,555 shares of the company’s stock, valued at $22,076.55. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. 23.92% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently bought and sold shares of TXMD. Amalgamated Bank increased its stake in shares of TherapeuticsMD by 7.2% in the second quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock worth $104,000 after purchasing an additional 1,322 shares in the last quarter. Principal Financial Group Inc. grew its holdings in TherapeuticsMD by 3.9% during the 2nd quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock valued at $114,000 after buying an additional 818 shares in the last quarter. Virtu KCG Holdings LLC purchased a new stake in TherapeuticsMD during the 2nd quarter valued at approximately $157,000. Quantbot Technologies LP purchased a new stake in TherapeuticsMD during the 3rd quarter valued at approximately $189,000. Finally, Cetera Investment Advisers purchased a new stake in TherapeuticsMD during the 2nd quarter valued at approximately $214,000. Hedge funds and other institutional investors own 73.69% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/therapeuticsmd-txmd-given-buy-rating-at-noble-financial/1776453.html.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.